A three-judge panel of the USPTO’s Patent Trial and Appeal Board found that Noven, a subsidiary of Japan-based Hisamitsu Pharmaceutical Co. Inc., had shown a reasonable chance of proving seven claims in U.S. Patent No. 6,335,031 B1 and that six claims in U.S....